Videos

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses how imaging can guide a women with breast cancer to make treatment decisions.

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, talks about the interaction between estrogen receptors (ER) and androgen receptors (AR) in patients with breast cancer.

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center and Georgetown University Medical Center, discusses pregnant patients with breast cancer.

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Kathy S. Albain, MD, from the Loyola University Chicago and Cardinal Bernardin Cancer Center, discusses the difference between the 21-gene (Oncotype DX) assay and 70-gene (MammaPrint) assay in breast cancer.

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.